NS Pharma Appoints New President to Oversee Next Phases of Orphan Drug Clinical Development and Commercialization
Sugiyama received a doctorate degree in organic chemistry from
In 2020, during the COVID-19 pandemic, Sugiyama transferred to NS Pharma in the US to work as assistant vice president overseeing commercial functions for VILTEPSO®(viltolarsen). In total, Sugiyama has worked for 28 years at
"Having served in both our science and patient focused fields, I have come to understand that having empathy for the patient is critical in the development of therapies to treat rare diseases," Sugiyama explained. "As president, it is my mission to maintain heightened levels of empathy at NS Pharma, and to enhance transparency between all stakeholders."
Sugiyama will lead the company through the next phases of clinical and commercial development for VILTEPSO and CAP-1002 (through a partnership with Capricor Therapeutics) – for the treatment of Duchenne muscular dystrophy (Duchenne). NS Pharma is also currently working on an exon 44 skipping therapy (Phase 2) and an exon 50 skipping therapy (Phase 1/2) for Duchenne, a selective JAK1 inhibition therapy for the treatment of eosinophilic granulomatosis with polyangiitis (EGPA), as well as several preclinical neurological therapies.
About
US Media Contact:
media@nspharma.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/ns-pharma-appoints-new-president-to-oversee-next-phases-of-orphan-drug-clinical-development-and-commercialization-302191606.html
SOURCE